Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Inhaled corticposteroids (ICS)
corticposteroids · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lebrikizumab | EXPERIMENTAL | Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8. |
| Placebo | PLACEBO_COMPARATOR | Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8. |
| Name | Type | Description |
|---|---|---|
| Lebrikizumab | DRUG | Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8. |
| Placebo | DRUG | Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8. |
| Inhaled corticposteroids (ICS) | DRUG | Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS. |
| Second Asthma Controller Medication | DRUG | Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study. |
Inclusion Criteria: * Asthma diagnosis for greater than or equal to (\>/=) 12 months prior to Visit 1 * Bronchodilator response demonstrated within the 12 months before Visit 1 or at Visit 1, 2, or 3 of screening * Pre-bronchodilator FEV1 of 40 percent (%) - 80% predicted at both Visits 2 and 3 * O...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Corticposteroids is an inhaled small molecule therapy being developed by Roche Holding AG for the treatment of asthma. It is also known as inhaled corticposteroids, or ICS. The drug is in Phase 2 clinical development and has been studied in a completed trial in adults with uncontrolled asthma.
Corticposteroids is being developed for the treatment of asthma, specifically in patients with uncontrolled asthma. It is an inhaled small molecule therapy. The development program is in Phase 2, and the drug has been evaluated in a completed clinical trial in adults with this condition.
Corticposteroids is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical program for this inhaled small molecule therapy in asthma.
Corticposteroids is in Phase 2 clinical development. It is an investigational inhaled small molecule therapy for asthma and has not been approved by the FDA. One Phase 2 trial has been completed, and no active trials are currently listed.
Corticposteroids has been studied in one completed Phase 2 trial, NCT02099656, titled A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma. The trial enrolled 64 adults across the United States, Canada, France, Ireland, Sweden, and the United Kingdom.
Yes, corticposteroids is also known as inhaled corticposteroids, or ICS. Both names refer to the same inhaled small molecule therapy being developed by Roche Holding AG for asthma. The drug is in Phase 2 development.